REPL News & Events

The Dow Jones closed slightly in positive territory, while the S&P 500 and Nasdaq were sharply higher after the April jobs report beat forecasts. Chip stocks rebounded after yesterday's pause, helping lift the Nasdaq back toward record territory. Oil briefly pushed back above $100 after renewed U.S.-Iran clashes in the Strait of Hormuz, but equities have largely treated each flare-up as temporary noise.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Nvidiawillin Irenand announced a partnership between the two companiesExpediareported, affirmed its FY26 revenue guidance, and announced a new $5B stock buyback authorizationAkamaireportedand provided its outlook for Q2 and FY26Blockprovided areport for Q1President Trump has signed off on a plan to fire Food and Drug Administration Commissioner Marty Makary,2. WALL STREET CALLS:BofAHubSpotto Underperform, while Citi, William Blair and Cantor Fitzgerald also downgraded HubSpot to Neutral-equivalent ratings after the company's Q1 results and commentaryDaiwaQualcommto OutperformWells FargoNiketo Equal WeightMorgan Stanley, TD Cowen and BofAPlanet Fitnessto Neutral-equivalent ratingsCraig-HallumAkamaito Buy3. AROUND THE WEB:PG&Ereleased an inquiry saying it was aware of damage at the Mission substation responsible for a December blackout in San Francisco but left the damaged equipment in place, SF Standard reportsAnthropic reached a cloud computing deal with Akamai, Bloomberg saysMeanwhile, Anthropic is weighing a deal for a nearly $1T valuation, FT reportsMeta'sAI push is causing anger and anxiety among the company's employees, NY Times reportsThe U.S. suspects Nvidiachips were smuggled tot Alibabavia Thailand, Bloomberg reports4. MOVERS:Monster Beverageadvanced after reportingArlo Technologiesrose afterand reiterating its FY26 outlookRocket Lab USAgained after providing anCloudflarefell after providing areport but also announcing 1,100 layoffsCoreWeavedeclined after reporting5. EARNINGS/GUIDANCE:Toyotareported a year-over-yearYelpand reiterated its FY26 revenue outlookGrouponreportedCoinbasereported a sharp drop inWendy'sreportedINDEXES:The Dow rose 12.19, or 0.025%, to 49,609.16, the Nasdaq gained 440.88, or 1.71%, to 26,247.08, and the S&P 500 advanced 61.82, or 0.84%, to 7,398.93.

Shares of Replimune (REPL) are trading higher on Friday after The Wall Street Journal reported that President Trump has signed off on a plan to fire the Food and Drug Administration Commissioner Marty Makary. Makary was the official at the center of the Replimune's RP1 melanoma therapy rejection, the same decision that drew heavy criticism from specialists and prompted last month's WSJ editorial defending the therapy. At the time, the Journal's The Editorial Board argued that the FDA's rejection of RP1 contradicted both expert opinion and the agency's own initial review panel, which had recommended approval. PRICE ACTION: In afternoon trading, Replimune jumped over 14% to $3.82.

In an opinion article, The Wall Street Journal's The Editorial Board argued that the Food and Drug Administration's rejection of Replimune's RP1 melanoma therapy contradicts both expert opinion and the agency's own initial review panel, which had recommended approval. According to the piece, FDA leadership replaced that panel with reviewers who still did not conclude the drug was ineffective, yet the agency denied approval based on what the article describes as flawed reasoning about trial design. Multiple melanoma specialists quoted in the article say RP1 has produced remissions in patients who had exhausted all other options, and they view the rejection as medically unsound and harmful to patients. Shares of Replimune have gained over 21%, trading at $2.26.